ANDA filing not “willful infringement”
The filing of an ANDA cannot constitute "willful infringement" under Waxman/ Hatch, a federal appeals court rules July 27. Federal Circuit reverses a Chicago judge's decision ordering Apotex to pay GlaxoSmithKline attorneys' fees in a Ceftin patent dispute (1"The Pink Sheet" June 2, 2003, p. 29). Apotex was enjoined from marketing its generic until the patents expired in July 2003...
You may also be interested in...
The pressure on generic companies to be first-to-file in patent challenges will lead to a "boom" in willful infringement cases against generics makers, an industry attorney maintains
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.